Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis

29 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

NICE, in confidence: an assessment of redaction to obscure confidential information in single technology appraisals by the National Institute for Health and Care Excellence

17 November 2019 - Health technology assessment aims to provide a transparent framework within which normative judgements can be applied for ...

Read more →

Tesaro's ovarian cancer drug Zejula added to Cancer Drugs Fund

1 June 2018 - Tesaro's ovarian cancer drug Zejula (niraparib), the first PARP inhibitor shown to be effective in patients ...

Read more →

The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges

20 February 2018 - Good practices for budget impact analysis have been increasingly developed since the year 2000.  ...

Read more →

NICE & PBAC outcomes differ for new heart failure drug Entresto

27 April 2016 - Around 100,000 people in England and Wales could now benefit from treatment with Novartis’ revolutionary heart failure ...

Read more →